January 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management

Oscar Pena/LinkedIn

Jan 9, 2026, 08:58

Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management

Oscar Pena, Chief Medical Resident at Hartford HealthCare, shared on LinkedIn:

”KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management

After more than a decade, KDIGO has released the 2026 Clinical Practice Guideline for Anemia in CKD.

This update incorporates evidence through late 2024, shifting how we handle iron, nomenclature, and novel therapies.
Here are the 5 critical takeaways for nephrology professionals:

1. New Terminology
To better reflect pathophysiology, “Systemic iron deficiency” replaces “absolute iron deficiency,” and “Iron-restricted erythropoiesis” replaces “functional iron deficiency.”

2. Proactive Iron for G5HD
Influenced by the PIVOTAL trial, the guideline suggests a proactive, high-dose IV iron strategy for patients on hemodialysis to reduce mortality/CV events.
• Initiate if: Ferritin ≤ 500 ng/ml and TSAT ≤ 30%.
• Upper limit: Withhold if Ferritin > 700 ng/ml or TSAT ≥ 40%.

3. ESAs Preferred Over HIF-PHIs
Despite the emergence of HIF-PHIs, ESAs remain the suggested first-line treatment due to safety data regarding MACE and thrombosis.

HIF-PHIs are reserved for ESA hyporesponsiveness and should be avoided in active malignancy.

4. Conservative Hb Targets
Consistent with past safety warnings, target Hb levels < 11.5 g/dl (115 g/l). Normalizing Hb (>13 g/dl) does not improve survival and increases stroke risk.

5. Restrictive Transfusions
Minimize transfusions to prevent allosensitization, specifically for transplant candidates. Treat based on symptoms, not arbitrary thresholds.”

Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management